LAVA-1278

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameLAVA-1278

Drug Alias NameLAVA-1278

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-CD40

TargetsTumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVu University Medical Center Lava Therapeutics NV

China Registration ClassN/A

Develop Information

Active CompaniesLava Therapeutics NV

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A